Novartis announced the US regulatory approval of Tyzeka(TM) (telbivudine) as a new once-a-day oral treatment for patients with chronic hepatitis B, a disease estimated to affect about 1.25 million people in the US but more than 350 million globally and considered the tenth leading cause of death.
The National Institutes of Health (NIH) has released a long range plan that will help to guide research in type 1 diabetes for the next decade. Advances and Emerging Opportunities in Type 1 Diabetes Research: A Strategic Plan identifies goals and objectives to exploit recent scientific advances in combating this autoimmune form of diabetes.
RESPeRATE is a portable, computerized electronic device that guides you through sessions of interactive, therapeutic breathing powerful enough to lower blood pressure.
In the U.K., Newham University Hospital NHS Trust has officially launched a telemedicine service that allows patients to self-monitor their conditions from their homes.
Silicon Valley lost 127,000 jobs, nine per cent of its employment, from the first quarter of 2001 to the second quarter of 2002, according to nonprofit group Joint Venture Silicon Valley losses were particularly acute among industries like software, semiconductors, computer and telecom hardware – which lost 22 percent of their jobs in a one-year period from 2001 to 2002.